Clinical Trial Update: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of the IL-15 superagonist N-803, with and without broadly neutralizing antibodies,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Broadly neutralizing antibodies (bnAbs) (broadly neutralizing antibodies)
• N-803

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infection | Phase 1 | Status: ACTIVE_NOT_RECRUITING